Page 15 of 27: studies 281 to 300 of 530, newest first. Back to the psilocybin overview
Scientific Data June 18, 2025 Subha Subramanian, Travis Rick Reneau, Demetrius Perry et al. correction
In this article the author’s name Travis Rick Reneau was incorrectly written as Travis Rick Renau. The original article has been corrected.
Journal of Psychedelic Studies June 17, 2025 Kevin Rebecchi
Abstract This 33-month retrospective case report explores the impact of psilocybin truffle intake on the emergence (and persistence) of mental imagery in an autistic woman with aphantasia. Aphantasia refers to the inability to generate visual mental images, which can significantly affect individuals' experiences and cognitive processes. The case study focuses on a 34-year-old autistic woman who...
June 16, 2025 Bénédicte Mannix, F. Leron Shults, Michael J. Winkelman
This chapter describes a psychedelic healing protocol developed by Bénédicte Mannix for treating childhood trauma, explaining its therapeutic approaches and the philosophical and psychological traditions that inform her healing practices. The motivation for the development of this protocol has been to harness the power of psilocybin to heal human minds, bodies, and souls from psychological...
Pharmacological Reports June 16, 2025 Tereza Klučková, Marek Nikolič, Filip Tylš et al. 4 citations
Recent studies intensively explore psilocybin's antidepressant potential, but variables like previous experience, repeated use, setting, and sex remain underexplored. This study examines acute and long-term effects of psilocybin in healthy individuals. A double-blind, placebo-controlled, cross-over study included 40 healthy participants (20 females, mean age 38). Each received two doses of...
Translational Psychiatry June 16, 2025 Ying Zhang, Lei Yang, Qiuyu Zhang et al. 6 citations
Psilocybin is among the most extensively studied psychedelics, with previous research suggesting its potential therapeutic role in suicide prevention. However, the precise mechanisms through which psilocybin may aid in suicide prevention remain unclear. This study thus employed network pharmacology and molecular docking tools to explore the mechanisms by which psilocybin may contribute to...
Cancer June 15, 2025 Manish Agrawal, Kim Roddy, Betsy Jenkins et al. 4 citations
Abstract Background Patients with cancer often struggle with depression, which can negatively impact quality of life as well as be challenging to manage. Methods A phase 2 trial was conducted that demonstrated safety, feasibility, and efficacy of a single dose of psilocybin combined with psychological support in a community cancer setting in 30 patients with cancer and a major depressive...
British Journal of Pharmacology June 15, 2025 Daniël Hoyer 9 citations
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N , N ‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone....
Translational Psychiatry June 14, 2025 Ines Erkizia-Santamaría, Igor Horrillo, Nerea Martínez-Álvarez et al. 16 citations
Abstract Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population. In the search for novel rapid-acting antidepressants, the psychedelic psilocybin has emerged as a promising therapy in several clinical...
Journal of Fungi June 13, 2025 Marco Pepe, Mohsen Hesami, Livia Fleishmann et al.
The resurgence of interest in the therapeutic potential of psilocybin-producing mushrooms has recently led to numerous research and commercialization efforts. Due to its ease of cultivation and high potency, Psilocybe is the primary genus of interest, and there is a growing need to standardize maintenance, proliferation, and cultivation techniques for efficient and consistent production. The...
Translational Psychiatry June 13, 2025 Tom Ben-Tal, Ilana Pogodin, Alexander Botvinnik et al. 2 citations
The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require administration in controlled clinical environments. This study investigates the synergistic benefits of combining psilocybin (PSIL) with...
June 10, 2025 Gabrielle Agin-Liebes, Petros Petridis, Richard J. Zeifman et al. 1 citation preprint
A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly improved drinking outcomes compared to an active placebo in adults with alcohol use disorder (AUD). In this secondary analysis, we assessed whether psilocybin-assisted therapy improved self-compassion and whether these changes predicted drinking...
Journal of CO2 Utilization June 10, 2025 Luke Lanham, Alistair R. Mctaggart, James R. Falconer
Mental health disorders and associated economic impact continue to rise domestically and globally. In 2023, to expand treatment options for individuals suffering Treatment Resistant Depression (TRD), the Therapeutic Goods Administration (TGA) of Australia has permitted psychiatrist lead psilocybin-assisted psychotherapy. Psilocybin, a psychedelic tryptamine found naturally in psychedelic...
Journal of Affective Disorders June 9, 2025 Sara Ellis, Catherine Bostian, Anna Donnelly et al. 3 citations
One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term outcomes of psilocybin in Veterans with severe TRD. This paper presents 12-month results from an open-label pilot study assessing the effects of 25 mg psilocybin in Veterans with severe TRD, defined as a major depressive episode failing to...
Therapeutic Advances in Psychopharmacology June 8, 2025 Nadav Liam Modlin, Victoria Williamson, Carolina Maggio et al. 1 citation
Post-traumatic stress disorder (PTSD) and associated trauma and stressor-related disorders are common and debilitating, presenting significant treatment challenges due to their complex interplay of biological, cognitive, affective, somatic and social factors. Current treatments, while advancing and effective, yield limited efficacy for many individuals, underscoring the need for novel...
Toxicon June 7, 2025 Simon A Beck, Caine Barlow, Liam Engel et al. 4 citations
Psilocybin-containing mushrooms have long been used for their psychoactive effects, but emerging evidence suggests that certain lignicolous ("wood-loving") species may also induce a distinct toxidrome known as "wood-lover paralysis" (WLP). WLP is characterised by transient weakness following mushroom ingestion, but its aetiology and prevalence remain poorly understood. In this paper, we present...
Scientific Data June 5, 2025 Subha Subramanian, Travis Rick Renau, Demetrius Perry et al. 4 citations
Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to...
European Journal of Medicinal Chemistry Reports June 3, 2025 Judith Stirn, Raphael Berger, Harald Hübner et al. 1 citation
4-Hydroxytryptamines such as psilocin and its prodrug psilocybin are of considerable current interest for innovative antidepressant and other neuropsychiatric treatments. We here present a synthetic route towards 4-hydroxytryptamines displaying a high versatility for SAR exploration at the aliphatic nitrogen. The core concept is to apply HATU-mediated amide couplings to a readily accessible and...
AJNR. American journal of neuroradiology June 3, 2025 Paloma C Frautschi, Ajay P Singh, Nicholas A Stowe et al. 2 citations
There is surging interest in the therapeutic potential of psychedelic compounds like psilocybin in the treatment of psychiatric illnesses like major depressive disorder (MDD). Recent studies point to the rapid antidepressant effect of psilocybin; however, the biologic mechanisms underlying these differences remain unknown. This study determines the feasibility of using diffusion MRI to...
Biuletyn Głównej Biblioteki Lekarskiej June 1, 2025 Christian S. Skowron, Urszula Miłkowska, Gabriela Maria Piech et al.
Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conventional therapies often yielding suboptimal outcomes. This narrative review examines the therapeutic potential of psilocybin and ketamine, two novel agents offering distinct mechanisms of action compared to traditional monoamine-based or monoamine...
Indian journal of microbiology June 1, 2025 Balakrishnan Karthiyayini, Nalliah Nithya Kalyani, Balakrishnan Gowdhami et al. 2 citations
The antimicrobial compound psilocybin possesses psychoactive properties with therapeutic applications. Psilocybin is the main component naturally present in psychedelic mushrooms and has been utilized in the treatment of depression and neurological disorders. In this study, psychedelic mushrooms were collected from Kodaikanal, Tamil Nadu. They underwent solvent extraction using High Performance...